"AIDS Treatment News" online * New Issue #302 (searchable/indexed)

Carlton Hogan carlton at walleye.ccbr.umn.edu
Mon Oct 5 10:46:34 EST 1998

In article <361545cd.83282293 at netnews.worldnet.att.net>,
 <johnburgin at worldnet.att.net> wrote:
>>  Protease inhibitors do not appear to be as
>>>toxic from the latest info that I have seen.
>>If you knew anything about the field that you blather on about,
>>you would know that proteases are virtually never prescribed without 
>>*2* drugs from AZT's class (nucleoside analogue reverse transcriptase
>>inhibitors) The most commonly prescribed protease-containing regimens
>>consist of AZT, 3TC, and a protease. That is one thing I have never 
>>seen any "dissident" be able to explain. If AZT is so toxic, how come
>>combining it with another drug in it's class, and a protease causes
>>death rates to drop in clinical endpoint trials?

>The short answer or the long one?  I prefer the short.  Less AZT
>combined with anything else in the PI category means less toxicity.

That *might* make sense, if the doses used in combo with the PIs
were not exactly the same as used in monotherapy.

>Why is that so confusing?  Am I missing something, do you contend that
>the same amounts of AZT are given "with" PI "therapy" as "recommended"
>alone?  There you have it, a "dissident "explains".jb

That is the fact. Before you jump in to the fray, learn the basics.


More information about the Immuno mailing list